The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies

Devinder S. Dhindsa, Pratik B. Sandesara, Michael D. Shapiro

    Research output: Contribution to journalReview articlepeer-review

    5 Scopus citations


    Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular, diabetes care and management of its attendant cardiovascular risk is now being revolutionized with the development and provision of the SGLT-2 inhibitors and GLP1-receptor agonists. Given the exciting data with these new classes of diabetes therapeutics, there is a clear need to improve education and utilization of these evidence-based medications across a wide spectrum of clinicians, including cardiologists. The aim of this review is to familiarize the cardiovascular specialist with the benefits and harms of the most commonly used oral anti- hyperglycemic medications, with an emphasis on SGLT-2 inhibitors and GLP-1 receptor agonists.

    Original languageEnglish (US)
    Article number160
    JournalFrontiers in Cardiovascular Medicine
    StatePublished - Nov 13 2018


    • GLP1-receptor agonists
    • SGLT-2 inhibitors
    • cardiovascular disease
    • cardiovascular outcomes trials
    • diabetes

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine


    Dive into the research topics of 'The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies'. Together they form a unique fingerprint.

    Cite this